PARP Inhibitors in Prostate Cancer.

Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP Inhibitors in Prostate Cancer. Curr Treat Options Oncol. 2017 06; 18(6):37.

View in: PubMed

subject areas

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Clinical Trials as Topic
Combined Modality Therapy
Disease Management
DNA Repair
Drug Resistance, Neoplasm
Gene Expression Regulation, Neoplastic
Humans
Male
Molecular Targeted Therapy
Mutation
Poly(ADP-ribose) Polymerase Inhibitors
Precision Medicine
Prostatic Neoplasms
Protein Binding
Transcription, Genetic
Treatment Outcome

authors with profiles

Matthew Schiewer

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement